Background and ObjectivesHematopoietic stem cell transplantation (HSCT), especially allogeneic HSCT (allo-HSCT), are now applied widely for the treatment of hematological or non-hematological malignancies, aplastic anemia and hereditary diseases. Graft versus host disease (GVHD) and opportunistic infection, which remain the main complications after allo-HSCT, lead to the high transplant-related mortality. GVHD and opportunistic infection lower the quality of life, and only about 50% patients with allo-HSCT [0] can get long term survival. To control GVHD and decrease the morbidity and mortality of opportunistic infection are the keys to prolong disease free survival and enhance quality of life of patients after allo-HSCT. Nowadays, the key to prolong disease free survival and enhance quality of life of patients is to induce immune torlerance for donor T cells to recipient antigen and enhance T cells reconstitution after allo-HSCT.During ontogenetic process, T cells acquire immune tolerance to self antigen and...
|